Targeted Riluzole Delivery by Antioxidant Nanovectors for Treating Amyotrophic Lateral Sclerosis
Abstract
The goal of this proposal is to determine whether hydrophilic carbon clusters (HCCs), that have exhibited potent antioxidant properties, can promote motorneuron integrity and enhance survival in a mouse model of amyotrophic lateral sclerosis. This project involves work performed at both UT-Health and Rice University; combining the cutting edge nanotechnology expertise of Dr. James Tour s laboratory at Rice with Dr. Grill s animal models at UT-Health. We are attempting to, first, determine whether Dr. Tour s HCCs can enhance motoneuron survival as well as overall lifespan in the G93A mouse model of ALS. In addition, we will also determine whether the HCCs, when combined with the current gold standard treatment for ALS, riluzole, will represent a new combinatorial therapy to improve outcome for patients living with ALS.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA598451
Entities
People
- Raymond J. Grill
Organizations
- University of Texas Health Science Center at Houston